Cargando…

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC

Up to 20% of all non-small cell lung cancer patients harbor tumor specific driver mutations that are effectively treated with tyrosine kinase inhibitors. However, for the rare EGFR deletion-insertion mutation of exon 18, there is very little evidence regarding the effectiveness of tyrosine kinase in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cekay, Michael, Arndt, Philipp F., Dumitrascu, Rio, Savai, Rajkumar, Braeuninger, Andreas, Gattenloehner, Stefan, Steiner, Dagmar, Roller, Fritz, Tello, Khodr, Hattar, Katja, Seeger, Werner, Sibelius, Ulf, Grimminger, Friedrich, Eul, Bastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466799/ https://www.ncbi.nlm.nih.gov/pubmed/37655099 http://dx.doi.org/10.3389/fonc.2023.1182391

Ejemplares similares

Reply to Zheng et al.
por: Eul, Bastian, et al.
Publicado: (2021)

Endotoxin induces proliferation of NSCLC in vitro and in vivo: role of COX-2 and EGFR activation
por: Hattar, Katja, et al.
Publicado: (2012)

Outpatient palliative care during the COVID-19 pandemic: a retrospective single centre analysis in Germany
por: Behnke, Jonas, et al.
Publicado: (2022)

Interactions between neutrophils and non-small cell lung cancer cells: enhancement of tumor proliferation and inflammatory mediator synthesis
por: Hattar, Katja, et al.
Publicado: (2014)

Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer
por: Kandra, Prameela, et al.
Publicado: (2022)

Lipoteichoic acids from Staphylococcus aureus stimulate proliferation of human non-small-cell lung cancer cells in vitro
por: Hattar, Katja, et al.
Publicado: (2017)

Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury
por: Dumitrascu, Rio, et al.
Publicado: (2008)

Hidden Treasures: Macrophage Long Non-Coding RNAs in Lung Cancer Progression
por: Karger, Annika, et al.
Publicado: (2021)

Macrophage and Tumor Cell Cross-Talk Is Fundamental for Lung Tumor Progression: We Need to Talk
por: Sarode, Poonam, et al.
Publicado: (2020)

Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report
por: Merkhofer, Cristina M., et al.
Publicado: (2021)

Long-term comprehensive cardiopulmonary phenotyping of COVID-19
por: Kimmig, Lucas M., et al.
Publicado: (2022)

Mitochondrial Respiration in Peripheral Blood Mononuclear Cells Negatively Correlates with Disease Severity in Pulmonary Arterial Hypertension
por: Sommer, Natascha, et al.
Publicado: (2022)

Wegener's Granulomatosis: Anti–proteinase 3 Antibodies Are Potent Inductors of Human Endothelial Cell Signaling and Leakage Response
por: Sibelius, Ulf, et al.
Publicado: (1998)

ω-3 vs. ω-6 lipid emulsions exert differential influence on neutrophils in septic shock patients: impact on plasma fatty acids and lipid mediator generation
por: Mayer, Konstantin, et al.
Publicado: (2003)

Correction to: Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice
por: Udalov, Sergey, et al.
Publicado: (2022)

Metabolism in tumour-associated macrophages: a quid pro quo with the tumour microenvironment
por: Zheng, Xiang, et al.
Publicado: (2020)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Picturing of the Lung Tumor Cellular Composition by Multispectral Flow Cytometry
por: Olesch, Catherine, et al.
Publicado: (2022)

Osimertinib for an Advanced NSCLC Patient with Two Common EGFR Mutations and a Concomitant MET Exon 14 Skipping Mutation: A Case Report
por: Liu, Zhicong, et al.
Publicado: (2023)

Exposomes to Exosomes: Exosomes as Tools to Study Epigenetic Adaptive Mechanisms in High-Altitude Humans
por: Padmasekar, Manju, et al.
Publicado: (2021)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Osimertinib in NSCLC: Real-World Data From New Zealand
por: So, Yeojeong Jane, et al.
Publicado: (2020)

The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC
por: Marwitz, Sebastian, et al.
Publicado: (2020)

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
por: Murano, Chihiro, et al.
Publicado: (2019)

Reply to Vanderpool et al.
por: Kremer, Nils, et al.
Publicado: (2023)

Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma
por: Banat, G-Andre, et al.
Publicado: (2015)

Complete Resolution of Sellar Metastasis in a Patient With NSCLC Treated With Osimertinib
por: Fan, WuQiang, et al.
Publicado: (2019)

Thin Air Resulting in High Pressure: Mountain Sickness and Hypoxia-Induced Pulmonary Hypertension
por: Grimminger, Jan, et al.
Publicado: (2017)

Estimated plasma volume status: association with congestion, cardiorenal syndrome and prognosis in precapillary pulmonary hypertension
por: Yogeswaran, Athiththan, et al.
Publicado: (2023)

Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
por: Scott, Lesley J.
Publicado: (2018)

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
por: Lamb, Yvette N.
Publicado: (2021)

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
por: Zheng, Mei-Mei, et al.
Publicado: (2022)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
por: Ye, Qiuyue, et al.
Publicado: (2023)

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
por: Ji, Jingran, et al.
Publicado: (2023)

The potential therapeutic regimen for overcoming resistance to osimertinib due to rare mutations in NSCLC
por: Han, Rui, et al.
Publicado: (2023)

PRMT-1 and p120-Catenin as EMT Mediators in Osimertinib Resistance in NSCLC
por: Racherla, Kavya Sri, et al.
Publicado: (2023)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
por: Wang, Jiao‐Li, et al.
Publicado: (2022)

Targeting CREB-binding protein overrides LPS induced radioresistance in non-small cell lung cancer cell lines
por: Gökyildirim, Mira Y., et al.
Publicado: (2018)

Evaluation of diagnostic accuracy of dual-energy computed tomography in patients with chronic thromboembolic pulmonary hypertension compared to V/Q-SPECT and pulmonary angiogram
por: Schüssler, Armin, et al.
Publicado: (2023)

Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
por: Scott, Lesley J.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rlhvftsu2aq07bkomq0ffqodm8